Economics of innovation

The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One target has come under particular scrutiny: rebates. A new report published by ICER and the OHE describes how alternatives to the current rebate system offer potential disadvantages as well as potential benefits. It outlines evidence presented to date and key questions that still need to be answered.

Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the top 10 causes of death in the world. The Center for Global Development and the Office of Health Economics are proposing a new innovation model to bring better TB drugs to market. We call it the “Market-Driven, Value-Based Advance Commitment,” or MVAC for short.

Pearson, S.

Seminar Briefing
February 2019

Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available publicly. This is exciting, but also offers serious and critical challenges in valuation. The focus of this seminar briefing is on those challenges.

OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.

Cole, A. and Towse, A.

Consulting Report
December 2018

The proliferation of health data in our ever more digitalised world of health care creates opportunities for better research around – and delivery of – pharmaceutical innovation. However, these opportunities may be constrained around the legal barriers to the use of health data for these purposes, which are poorly understood, particularly in relation to the new General Data Protection Regulation (GDPR).

Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session.

OHE staff recently attended the ISPOR Europe conference in Barcelona. In this blog post, we share a selection of our presentations.

Neri, M., Towse, A. and Garau, M.

Briefing
December 2018

This report provides a detailed summary of a panel discussion held at the HTAi 2017 annual meeting in Rome on the current approaches to MIP in Europe, the perceived challenges, and how they could be tackled in the future.

The Office of Health Economics

Briefing
November 2018

This is OHE’s report to the Charity Commission for England and Wales for the year 2017, OHE’s first since becoming a registered charity in December 2016. It demonstrates some of the ways in which OHE has met its charitable objects: namely, to advance the education of the public in general/health care payers/policy makers on the subject of health economics and health care policy.

A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores potential solutions to these challenges. Three key topics are explored: uncertainty, discounting, and health outcomes and value. A series of recommendations are proposed.

Pages

Subscribe to RSS - Economics of innovation